MARKET

LMNL

LMNL

Liminal Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.500
-0.500
-10.00%
Opening 11:44 10/30 EDT
OPEN
5.00
PREV CLOSE
5.00
HIGH
5.18
LOW
4.400
VOLUME
384.03K
TURNOVER
--
52 WEEK HIGH
31.45
52 WEEK LOW
4.400
MARKET CAP
106.33M
P/E (TTM)
0.2448
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Liminal BioSciences secures equity funding of $30M
Liminal BioSciences (LMNL) ticks 8% higher in premarket on private placement led by an undisclosed U.S. public investment fund, as well as an existing investor, Structured Alpha, to purchase ~$30M shares, warrants and pre-funded
Seekingalpha · 2h ago
Liminal BioSciences Announces Private Placement Financing Of USD$30 Million
LAVAL, QC, and CAMBRIDGE, ENGLAND, Oct. 30, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical
Benzinga · 3h ago
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 1d ago
48North Cannabis Corp. launches Latitude, a brand with products ranging from sexual wellness, to beauty and beyond
TORONTO, Oct. 15, 2020 /CNW/ - 48North Cannabis Corp.
CNW Group · 10/15 14:12
Canada and Nova Scotia invest in a new community centre for Sheet Harbour
HALIFAX, NS, Oct. 7, 2020 /CNW/ - The safety and well-being of Canadians are top priorities of the governments of Canada and Nova Scotia.
CNW Group · 10/07 14:30
Liminal BioSciences Provides Update on Progress on BLA for Ryplazim®(plasminogen)
Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration ("FDA") acknowledged receipt of the resubmission, by its US subsidiary, Prometic Biotherapeutics
PR Newswire · 09/21 13:16
Liminal BioSciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference
Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at The H.C. Wainwright 22nd Annual
PR Newswire · 09/09 12:00
Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen) for Treatment of Congenital Plasminogen Deficiency
* Results from pivotal phase 2/3 study met co-primary endpoints for improvement in trough plasminogen activity levels and reduction in lesion size * Pending approval, potential for Ryplazim® (plasminogen) to be first FDA-approved therapy for treatment of congenital plasminogen deficiencyLAVAL, QC and
CNW Group · 09/08 11:00
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LMNL. Analyze the recent business situations of Liminal Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LMNL stock price target is 12.82 with a high estimate of 15.78 and a low estimate of 9.87.
EPS
Institutional Holdings
Institutions: 15
Institutional Holdings: 3.37M
% Owned: 14.28%
Shares Outstanding: 23.63M
TypeInstitutionsShares
Increased
3
5.92K
New
5
33.55K
Decreased
2
1.78K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.63%
Pharmaceuticals & Medical Research
-1.25%
Key Executives
Non-Executive Chairman
Aleksander Krstajic
Chief Executive Officer/Director
Kenneth Galbraith
Chief Financial Officer
Murielle Lortie
Chief Operating Officer/IR Contact Officer
Bruce Pritchard
Chief Operating Officer
Patrick Sartore
Chief Human Resource Officer
Martin Leclerc
General Counsel
Marie Iskra
Other
Moira Daniels
Lead Director/Independent Director
Simon Best
Director
Eugene Siklos
Independent Director
Gary Bridger
Independent Director
Neil Klompas
Independent Director
Timothy Wach
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LMNL
Liminal BioSciences Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for patients suffering from diseases primarily related to fibrosis, including respiratory, liver and kidney diseases. The Company operates through two segments: Small Molecule Therapeutics Segment and Plasma-derived Therapeutics Segment. The Small Molecule Therapeutics Segment is a small-molecule drug development business. Its lead small molecule product candidate is fezagepras (PBI-4050). The Plasma-derived Therapeutics Segment includes its plasma-derived therapeutics platform, which enables the development of its pipeline of biopharmaceutical candidates. Its lead plasma-derived product candidate is Ryplazim (plasminogen).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Liminal BioSciences Inc stock information, including NASDAQ:LMNL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LMNL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LMNL stock methods without spending real money on the virtual paper trading platform.